The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Jefferies analyst Dennis Ding has issued a positive outlook for Mineralys Therapeutics (MLYS), setting a price target of $30 per share. This target implies a potential upside of 14.37% from current levels, reflecting confidence in the company's clinical pipeline. The recommendation follows the company’s Q4 2025 earnings call, where management outlined strategic growth plans within the cardiovascular and renal disease sectors. Despite the optimistic forecast, the stock has experienced significant volatility over the past year, trading between a low of $10.44 and a high of $47.65. Investors are closely monitoring the company's R&D progress as it seeks to address unmet medical needs in its core therapeutic areas. The bullish sentiment from Jefferies underscores the long-term potential of MLYS's specialized drug development programs.